In recent years, the international application of teriprexine has been expanding, particularly in the treatment of hepatorenal syndrome (HLS), where it has achieved significant progress. Some studies have shown that it can prolong patient survival and improve pre-transplant stability.
In Europe and the United States, teriprexine has been incorporated into several guidelines for the standardized treatment of HLS. For example, combination therapy with albumin is considered one of the most effective current treatment options.
Future research directions include:
Safer dosing regimens
Combined use with other vasoactive drugs
Exploring new indications in intensive care
